Davion Healthcare appoints new CFO and non-executive director

Davion Healthcare Plc announced the appointment of Andreas Ttofi as Chief Financial Officer and Jan Dulman as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Ttofi is an ACCA Member with over a decade of experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised corporate and private clients across multiple sectors, according to the company statement.

Dulman is a Certified Public Accountant with experience as a CFO, audit professional, and senior accounting partner. He previously served as Controller and CFO of a publicly listed mining exploration company and founded a CPA partnership that was later merged into a national practice. Dulman has overseen SEC filings, including what the company described as one of the largest Regulation A registrations in U.S. history.

The medical technology company develops non-invasive home tests for medical conditions including cancer. Its lead product, BreastCheck, is an FDA-registered at-home breast health screening test scheduled for commercial launch by the end of the first half of 2026.

Davion operates through a licensing-led model, designing and registering monitoring tools while partnering with third parties for manufacturing and distribution. The company is preparing for a NASDAQ Global Market listing under the ticker DAVI.

The company's product pipeline includes FootFlow for foot temperature monitoring, Testic for testicular health monitoring, and ThermaDerm for skin anomaly detection.

Chairman Sir Eric Peacock stated the appointments strengthen the board as the company advances toward its NASDAQ listing and global expansion plans.

You May Also Be Interested In

• SS Innovations names Sarah M. Romano as CFO, effective August 3
• flyExclusive completes acquisition of Jet.AI aviation assets
• Ligand completes $739M acquisition of XOMA Royalty